One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin

  • Authors: Daniel B. Brown, Carin F. Gonsalves, Charles J. Yeo, Agnes K. Witkiewicz, Brian I. Carr
  • View Affiliations

  • Published online on: Wednesday, September 1, 2010
  • Pages: 767-769
  • DOI: 10.3892/or_00000919

Abstract

While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.
Journal Cover

September 2010
Volume 24 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

2012 Impact Factor: 2.297
Ranked #36/196 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Brown, D., Gonsalves, C., Yeo, C., Witkiewicz, A., & Carr, B. (2010). One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin . Oncology Reports, 24(3), 767-769.
MLA
Brown, Gonsalves, Yeo, Witkiewicz, and Brian Carr. "One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin ." Oncology Reports Oncology Reports 24.3 (2010): 767-769.
Chicago
Brown, Gonsalves, Yeo, Witkiewicz, and Brian Carr. "One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin ." Oncology Reports Oncology Reports 24 no. 3 (2010): 767-769.